Literature DB >> 18492710

Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production.

R J Pepper, M A Fabre, C Pavesio, G Gaskin, R B Jones, D Jayne, C D Pusey, A D Salama.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18492710     DOI： 10.1093/rheumatology/ken175

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  22 in total

Review 1.  Innate immune cells in the pathogenesis of primary systemic vasculitis.

Authors:  Durga Prasanna Misra; Vikas Agarwal
Journal:  Rheumatol Int       Date:  2015-09-24       Impact factor: 2.631

Review 2.  Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis.

Authors:  Jeremy M Clain; Rodrigo Cartin-Ceba; Fernando C Fervenza; Ulrich Specks
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-04       Impact factor: 5.346

3.  Churg-Strauss syndrome successfully treated with rituximab.

Authors:  Kristin Kveim Dønvik; Roald Omdal
Journal:  Rheumatol Int       Date:  2009-09-30       Impact factor: 2.631

4.  Successful use of Rituximab in a patient with recalcitrant multisystemic eosinophilic granulomatosis with polyangiitis.

Authors:  Catherine E Najem; Rajwardhan Yadav; Elise Carlson
Journal:  BMJ Case Rep       Date:  2015-05-15

Review 5.  Eosinophilic Vasculitis.

Authors:  Karen L Vega Villanueva; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2020-01-11       Impact factor: 4.592

6.  Signal transducer and activation of transcription 6 (STAT6) regulates T helper type 1 (Th1) and Th17 nephritogenic immunity in experimental crescentic glomerulonephritis.

Authors:  S A Summers; R K S Phoon; D Odobasic; L Dewage; A R Kitching; S R Holdsworth
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

7.  Bowel perforations in a patient affected by Churg-Strauss syndrome under high-dose steroid treatment: will alternative drugs reduce risk of surgery?

Authors:  Dario Venditti; Balassone Valerio; Benedetto Ielpo; Oreste Buonomo; Giuseppe Petrella
Journal:  Rheumatol Int       Date:  2009-12-12       Impact factor: 2.631

Review 8.  Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review.

Authors:  Loïc Raffray; Loïc Guillevin
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546

Review 9.  Eosinophils in vasculitis: characteristics and roles in pathogenesis.

Authors:  Paneez Khoury; Peter C Grayson; Amy D Klion
Journal:  Nat Rev Rheumatol       Date:  2014-07-08       Impact factor: 20.543

Review 10.  Targeting the B cell in vasculitis.

Authors:  Michael Walsh; David Jayne
Journal:  Pediatr Nephrol       Date:  2008-10-18       Impact factor: 3.714
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.